NCT03387904 is a Phase 2 clinical trial of Anlotinib Plus Irinotecan in Esophageal Squamous Cell Carcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University.

Who is sponsoring NCT03387904?

NCT03387904 is sponsored by The First Affiliated Hospital of Zhengzhou University.

What drugs are being tested in NCT03387904?

Interventions in NCT03387904: Anlotinib Plus Irinotecan, Irinotecan.

What condition does NCT03387904 study?

NCT03387904 studies Esophageal Squamous Cell Carcinoma.

Is NCT03387904 still recruiting?

NCT03387904 is currently status unknown. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT03387904

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 2 September 2021

What this trial tests

Phase 2 trial testing Anlotinib Plus Irinotecan in Esophageal Squamous Cell Carcinoma in 120 participants. Status unknown.

Timeline

13 January 2019

Primary endpoint
1 December 2021

1 December 2022

Quick facts

Lead sponsor	The First Affiliated Hospital of Zhengzhou University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	13 January 2019
Primary completion	1 December 2021
Estimated completion	1 December 2022
Sites	1 location across China

Drugs / interventions tested

Anlotinib Plus Irinotecan — full drug profile →
Irinotecan (irinotecan) — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

The First Affiliated Hospital of Zhengzhou University

Who can join

Adults 18 to 75, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Anlotinib as a molecular targeted therapy for tumors.
Gao Y, Liu P, Shi R. · · 2020 · cited 108× · PMID 32724339 · DOI 10.3892/ol.2020.11685
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma.
Ooki A, Osumi H, Chin K, Watanabe M, et al · · 2023 · cited 17× · PMID 36872946 · DOI 10.1177/17588359221138377
Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review).
Li Y, Li J, Mo W, Xu X. · · 2025 · PMID 40682837 · DOI 10.3892/or.2025.8953

Verify or expand the search:

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other The First Affiliated Hospital of Zhengzhou University trials

Trials by the same sponsor.

NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03387904 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03387904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing